Literature DB >> 32426097

Short term outcomes of minimally invasive selective lateral pelvic lymph node dissection for low rectal cancer.

Kar Yong Wong1, Aloysius Mn Tan2.   

Abstract

BACKGROUND: Pelvic recurrence after rectal cancer surgery is still a significant problem despite the introduction of total mesorectal excision and chemoradiation treatment (CRT), and one of the most common areas of recurrence is in the lateral pelvic lymph nodes. Hence, there is a possible role for lateral pelvic lymph node dissection (LPND) in rectal cancer. AIM: To evaluate the short-term outcomes of patients who underwent minimally invasive LPND during rectal cancer surgery. Secondary outcomes were to evaluate for any predictive factors to determine lymph node metastases based on pre-operative scans.
METHODS: From October 2016 to November 2019, 22 patients with stage II or III rectal cancer underwent minimally invasive rectal cancer surgery and LPND. These patients were all discussed at a multidisciplinary tumor board meeting and most of them received neoadjuvant chemoradiation prior to surgery. All patients had radiologically positive lateral pelvic lymph nodes on the initial staging scans, defined as lymph nodes larger than 7 mm in long axis measurement, or abnormal radiological morphology. LPND was only performed on the involved side.
RESULTS: Majority of the patients were male (18/22, 81.8%), with a median age of 65 years (44-81). Eighteen patients completed neoadjuvant CRT pre-operatively. 18 patients (81.8%) had unilateral LPND, with the others receiving bilateral surgery. The median number of lateral pelvic lymph nodes harvested was 10 (3-22) per pelvic side wall. 8 patients (36.4%) had positive metastases identified in the lymph nodes harvested. The median pre-CRT size of these positive lymph nodes was 10mm. Median length of stay was 7.5 d (3-76), and only 2 patients failed initial removal of their urinary catheter. Complication rates were low, with only 1 lymphocele and 1 anastomotic leak. There was only 1 mortality (4.5%). There have been no recurrences so far.
CONCLUSION: Chemoradiation is inadequate in completely eradicating lateral wall metastasis and there are still technical limitations in accurately diagnosing metastases in these areas. A pre-CRT lymph node size of ≥ 10 mm is suggestive of metastases. LPND may be performed safely with minimally invasive surgery. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Lateral pelvic lymph node dissection; Local recurrence; Locally advanced rectal cancer; Pelvic side wall recurrence; Robotic rectal surgery

Year:  2020        PMID: 32426097      PMCID: PMC7215974          DOI: 10.4240/wjgs.v12.i4.178

Source DB:  PubMed          Journal:  World J Gastrointest Surg


  16 in total

1.  Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection.

Authors:  Tae Hyun Kim; Seung-Yong Jeong; Dong Hyun Choi; Dae Yong Kim; Kyung Hae Jung; Sung Ho Moon; Hee Jin Chang; Seok-Byung Lim; Hyo Seong Choi; Jae-Gahb Park
Journal:  Ann Surg Oncol       Date:  2007-12-05       Impact factor: 5.344

2.  Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.

Authors:  Atsushi Ogura; Tsuyoshi Konishi; Chris Cunningham; Julio Garcia-Aguilar; Henrik Iversen; Shigeo Toda; In Kyu Lee; Hong Xiang Lee; Keisuke Uehara; Peter Lee; Hein Putter; Cornelis J H van de Velde; Geerard L Beets; Harm J T Rutten; Miranda Kusters
Journal:  J Clin Oncol       Date:  2018-11-07       Impact factor: 44.544

Review 3.  Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis.

Authors:  Panagiotis Georgiou; Emile Tan; Nikolaos Gouvas; Anthony Antoniou; Gina Brown; R John Nicholls; Paris Tekkis
Journal:  Lancet Oncol       Date:  2009-09-18       Impact factor: 41.316

4.  Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer.

Authors:  M Ueno; M Oya; K Azekura; T Yamaguchi; T Muto
Journal:  Br J Surg       Date:  2005-06       Impact factor: 6.939

5.  Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease?

Authors:  Takashi Akiyoshi; Toshiaki Watanabe; Satoshi Miyata; Kenjiro Kotake; Tetsuichiro Muto; Kenichi Sugihara
Journal:  Ann Surg       Date:  2012-06       Impact factor: 12.969

6.  Outcomes of surgery alone for lower rectal cancer with and without pelvic sidewall dissection.

Authors:  Hirotoshi Kobayashi; Hidetaka Mochizuki; Tomoyuki Kato; Takeo Mori; Shingo Kameoka; Kazuo Shirouzu; Kenichi Sugihara
Journal:  Dis Colon Rectum       Date:  2009-04       Impact factor: 4.585

7.  Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.

Authors:  Takashi Akiyoshi; Masashi Ueno; Kiyoshi Matsueda; Tsuyoshi Konishi; Yoshiya Fujimoto; Satoshi Nagayama; Yosuke Fukunaga; Toshiyuki Unno; Atsuhiro Kano; Hiroya Kuroyanagi; Masatoshi Oya; Toshiharu Yamaguchi; Toshiaki Watanabe; Tetsuichiro Muto
Journal:  Ann Surg Oncol       Date:  2013-08-21       Impact factor: 5.344

8.  Prevention of local recurrence by extended lymphadenectomy for rectal cancer.

Authors:  K Suzuki; T Muto; T Sawada
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 9.  Nodal drainage pathways in primary rectal cancer: anatomy of regional and distant nodal spread.

Authors:  Harmeet Kaur; Randy D Ernst; Gaiane M Rauch; Mukesh Harisinghani
Journal:  Abdom Radiol (NY)       Date:  2019-11

10.  Optimal treatment strategies for clinically suspicious lateral pelvic lymph node metastasis in rectal cancer.

Authors:  Hye Jin Kim; Gyu-Seog Choi; Jun Seok Park; Soo Yeun Park; Seung Hyun Cho; Soo Jung Lee; Byung Woog Kang; Jong Gwang Kim
Journal:  Oncotarget       Date:  2017-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.